| Molecular formula | C17H23N7O5 |
|---|
| Molecular weight | 405.4 g/mol |
|---|
| Registered trials | 1 |
|---|
| PubChem CID | 114750 |
|---|
Taltirelin is being studied in a research context, and this overview summarizes what is publicly documented rather than any approved use. It draws only on registered trial records and chemical identity data.
What taltirelin is
Taltirelin is a synthetic compound identified by PubChem CID 114750, with the molecular formula C17H23N7O5 and a molecular weight of 405.4. No approved drug label is associated with this compound in the data reviewed, so no indications, mechanism, or brand names can be reported here. Its status here is investigational and it is not described as approved for any use.
Trial footprint
One registered trial referencing this compound appears in the dataset reviewed. That trial, "C-Trelin Orally Disintegrated (OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration" (NCT04107740), is listed with a completed status. No additional registered trials beyond this one were found in the data reviewed.
FAQ
No approved drug label for taltirelin was found in the data reviewed. It is best understood as an investigational compound rather than an approved treatment.
Taltirelin is a synthetic compound with the molecular formula C17H23N7O5 and a molecular weight of 405.4. It is catalogued in PubChem under CID 114750.
The data reviewed shows one registered trial referencing taltirelin. That trial, focused on an orally disintegrating tablet formulation in ataxia due to spinocerebellar degeneration, is listed as completed.
No side effect or adverse event report data was available for taltirelin in the sources reviewed. This means no report-based safety pattern can be summarized here.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-09-26